Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Chinese Journal of Pathology ; (12): 257-261, 2005.
Article in Chinese | WPRIM | ID: wpr-265130

ABSTRACT

<p><b>OBJECTIVE</b>The FHIT (fragile histidine triad) is a candidate tumor suppressor gene (TSG) located on chromosome 3p14.2. Hypermethylation and loss of heterozygosity (LOH) are major mechanisms in the inactivation of tumor suppressor genes. In this study, the methylation status of FHIT and LOH of 3p14 in 61 cases of human sporadic ovary carcinomas were investigated.</p><p><b>METHODS</b>Sixty-one primary ovary carcinomas and 10 borderline ovarian tumors were analyzed with methylation specific PCR (MSP) to detect the CpG island methylation status in the FHIT promoter region. In addition, 45 cases of ovary carcinomas and their corresponding non-tumor ovary tissues were investigated with D3S1287 microsatellite polymorphic marker for LOH.</p><p><b>RESULTS</b>Hypermethylation of FHIT gene was observed in 39.3% (24/61) of ovarian carcinomas. The frequencies of hypermethylation in serous ovarian carcinoma, mucinous ovarian carcinoma, endometrioid ovarian carcinoma and ovary borderline tumor were 45.2% (19/42), 14.3% (1/7), 33.3% (4/12) and 60.0% (6/10), respectively. Ten of twenty-three (43.5%) informative tumors showed LOH and 6 of 18 (33.3%) informative cases showed homozygous deletions. The status of FHIT methylation was not associated with clinical stage and differentiation grade, there was no significant difference between the malignant and borderline tumors.</p><p><b>CONCLUSION</b>Hypermethylation and allelic deletion of FHIT are frequent events in ovarian carcinomas and are important mechanisms for the loss of expression of this gene.</p>


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Acid Anhydride Hydrolases , Genetics , Metabolism , Chromosomes, Human, Pair 3 , CpG Islands , Cystadenocarcinoma, Serous , Genetics , Metabolism , DNA Methylation , DNA, Neoplasm , Genetics , Genes, Tumor Suppressor , Loss of Heterozygosity , Neoplasm Proteins , Genetics , Metabolism , Ovarian Neoplasms , Genetics , Metabolism
SELECTION OF CITATIONS
SEARCH DETAIL